Published in Placenta on August 01, 2005
Preeclampsia, a disease of the maternal endothelium: the role of antiangiogenic factors and implications for later cardiovascular disease. Circulation (2011) 2.55
Cardiac angiogenic imbalance leads to peripartum cardiomyopathy. Nature (2012) 2.27
The effect of immune factors, tumor necrosis factor-alpha, and agonistic autoantibodies to the angiotensin II type I receptor on soluble fms-like tyrosine-1 and soluble endoglin production in response to hypertension during pregnancy. Am J Hypertens (2010) 2.23
Complement activation induces dysregulation of angiogenic factors and causes fetal rejection and growth restriction. J Exp Med (2006) 2.16
Transcriptionally active syncytial aggregates in the maternal circulation may contribute to circulating soluble fms-like tyrosine kinase 1 in preeclampsia. Hypertension (2012) 1.86
A prospective cohort study of the value of maternal plasma concentrations of angiogenic and anti-angiogenic factors in early pregnancy and midtrimester in the identification of patients destined to develop preeclampsia. J Matern Fetal Neonatal Med (2009) 1.84
Recent progress toward the understanding of the pathophysiology of hypertension during preeclampsia. Hypertension (2008) 1.72
Hypertension and maternal-fetal conflict during placental malaria. PLoS Med (2006) 1.56
Molecular mechanisms of peripartum cardiomyopathy: A vascular/hormonal hypothesis. Trends Cardiovasc Med (2015) 1.54
The soluble VEGF receptor sFlt1 contributes to endothelial dysfunction in CKD. J Am Soc Nephrol (2009) 1.50
Beyond oxygen: complex regulation and activity of hypoxia inducible factors in pregnancy. Hum Reprod Update (2009) 1.29
Removal of Soluble Fms-Like Tyrosine Kinase-1 by Dextran Sulfate Apheresis in Preeclampsia. J Am Soc Nephrol (2015) 1.25
The role of immune activation in contributing to vascular dysfunction and the pathophysiology of hypertension during preeclampsia. Minerva Ginecol (2010) 1.23
First-trimester maternal serum PP13 in the risk assessment for preeclampsia. Am J Obstet Gynecol (2008) 1.08
Novel soluble Flt-1 isoforms in plasma and cultured placental explants from normotensive pregnant and preeclamptic women. Placenta (2008) 1.07
Late-onset preeclampsia is associated with an imbalance of angiogenic and anti-angiogenic factors in patients with and without placental lesions consistent with maternal underperfusion. J Matern Fetal Neonatal Med (2011) 1.07
Emerging role of relaxin in the maternal adaptations to normal pregnancy: implications for preeclampsia. Semin Nephrol (2011) 1.03
Angiogenic factors in preeclampsia and related disorders. Cold Spring Harb Perspect Med (2012) 0.99
Placental ischemia and cardiovascular dysfunction in preeclampsia and beyond: making the connections. Expert Rev Cardiovasc Ther (2008) 0.94
L-arginine supplementation abolishes the blood pressure and endothelin response to chronic increases in plasma sFlt-1 in pregnant rats. Am J Physiol Regul Integr Comp Physiol (2011) 0.93
Nicotine inhibits cytokine production by placenta cells via NFkappaB: potential role in pregnancy-induced hypertension. Mol Med (2007) 0.93
Microbial invasion of the amniotic cavity in preeclampsia as assessed by cultivation and sequence-based methods. J Perinat Med (2010) 0.92
Maternal circulating levels of activin A, inhibin A, sFlt-1 and endoglin at parturition in normal pregnancy and pre-eclampsia. PLoS One (2009) 0.92
Twin-to-twin transfusion syndrome: an antiangiogenic state? Am J Obstet Gynecol (2008) 0.92
Placental growth hormone is increased in the maternal and fetal serum of patients with preeclampsia. J Matern Fetal Neonatal Med (2007) 0.91
Midpregnancy levels of angiogenic markers in relation to maternal characteristics. Am J Obstet Gynecol (2010) 0.89
Effect of antihypertensive therapy with alpha methyldopa on levels of angiogenic factors in pregnancies with hypertensive disorders. PLoS One (2008) 0.89
Preeclampsia and pregnancies with small-for-gestational age neonates have different profiles of complement split products. J Matern Fetal Neonatal Med (2010) 0.88
Circulating angiogenic and antiangiogenic factors in women with eclampsia. Am J Obstet Gynecol (2010) 0.88
Role of biomarkers in early detection of preeclampsia. J Clin Diagn Res (2014) 0.88
Agonistic autoantibodies to the angiotensin II type I receptor cause pathophysiologic characteristics of preeclampsia. Gend Med (2012) 0.87
Design of growth factor sequestering biomaterials. Chem Commun (Camb) (2014) 0.87
Maternal serum soluble CD30 is increased in normal pregnancy, but decreased in preeclampsia and small for gestational age pregnancies. J Matern Fetal Neonatal Med (2007) 0.86
Tissue factor and its natural inhibitor in pre-eclampsia and SGA. J Matern Fetal Neonatal Med (2008) 0.86
Expression of the sFLT1 gene in cord blood cells is associated to maternal arsenic exposure and decreased birth weight. PLoS One (2014) 0.85
Integrating multiple 'omics' analyses identifies serological protein biomarkers for preeclampsia. BMC Med (2013) 0.85
Unexplained fetal death is associated with increased concentrations of anti-angiogenic factors in amniotic fluid. J Matern Fetal Neonatal Med (2010) 0.85
Over-expression of the thrombin receptor (PAR-1) in the placenta in preeclampsia: a mechanism for the intersection of coagulation and inflammation. J Matern Fetal Neonatal Med (2008) 0.84
Angiogenic, hyperpermeability and vasodilator network in utero-placental units along pregnancy in the guinea-pig (Cavia porcellus). Reprod Biol Endocrinol (2008) 0.84
Relaxin-2 and Soluble Flt1 Levels in Peripartum Cardiomyopathy: Results of the Multicenter IPAC Study. JACC Heart Fail (2016) 0.83
Altered matrix metalloproteinase-2 and -9 expression/activity links placental ischemia and anti-angiogenic sFlt-1 to uteroplacental and vascular remodeling and collagen deposition in hypertensive pregnancy. Biochem Pharmacol (2014) 0.83
Serum and plasma determination of angiogenic and anti-angiogenic factors yield different results: the need for standardization in clinical practice. J Matern Fetal Neonatal Med (2010) 0.83
Peptidomic Identification of Serum Peptides Diagnosing Preeclampsia. PLoS One (2013) 0.83
Association of Maternal Antiangiogenic Profile at Birth With Early Postnatal Loss of Microvascular Density in Offspring of Hypertensive Pregnancies. Hypertension (2016) 0.81
Acute pyelonephritis during pregnancy changes the balance of angiogenic and anti-angiogenic factors in maternal plasma. J Matern Fetal Neonatal Med (2010) 0.81
Do anti-angiogenic or angiogenic factors contribute to the protection of birth weight at high altitude afforded by Andean ancestry? Reprod Sci (2010) 0.81
Synthesis of sFlt-1 by platelet-monocyte aggregates contributes to the pathogenesis of preeclampsia. Am J Obstet Gynecol (2014) 0.80
Reduced uterine perfusion pressure induces hypertension in the pregnant mouse. Am J Physiol Regul Integr Comp Physiol (2014) 0.79
Molecular Mechanisms of Preeclampsia. Cold Spring Harb Perspect Med (2015) 0.78
Dinucleotide repeat polymorphism in Fms-like tyrosine kinase-1 (Flt-1) gene is not associated with preeclampsia. BMC Med Genet (2008) 0.77
Inflammatory pattern recognition receptors and their ligands: factors contributing to the pathogenesis of preeclampsia. Inflamm Res (2011) 0.76
Ouabain inhibits placental sFlt1 production by repressing HSP27-dependent HIF-1α pathway. FASEB J (2014) 0.76
Soluble VEGF receptor 1 (sFLT1) induces non-apoptotic death in ovarian and colorectal cancer cells. Sci Rep (2016) 0.76
The role of decidual cells in uterine hemostasis, menstruation, inflammation, adverse pregnancy outcomes and abnormal uterine bleeding. Hum Reprod Update (2016) 0.76
Preeclampsia, hypoxia, thrombosis, and inflammation. J Pregnancy (2011) 0.76
Sodium hydrosulfide prevents hypertension and increases in vascular endothelial growth factor and soluble fms-like tyrosine kinase-1 in hypertensive pregnant rats. Naunyn Schmiedebergs Arch Pharmacol (2016) 0.75
Regulation of soluble fms-like tyrosine kinase-1 production in response to placental ischemia/hypoxia: role of angiotensin II. Physiol Rep (2015) 0.75
Predictors of Impaired Postpartum Renal Function in Women after Preeclampsia: Results of a Prospective Single Center Study. Dis Markers (2016) 0.75
Relationships among maternal nutrient intake and placental biomarkers during the 1st trimester in low-income women. Arch Gynecol Obstet (2012) 0.75
Mid-pregnancy levels of angiogenic markers as indicators of pathways to preterm delivery. J Matern Fetal Neonatal Med (2011) 0.75
Expression levels of seven candidate genes in human peripheral blood mononuclear cells and their association with preeclampsia. Hypertens Pregnancy (2013) 0.75
Maternal and fetoplacental hypoxia do not alter circulating angiogenic growth effectors during human pregnancy. Biol Reprod (2014) 0.75
Targeted complement inhibition and microvasculature in transplants: a therapeutic perspective. Clin Exp Immunol (2015) 0.75
Matrix Metalloproteinases in Normal Pregnancy and Preeclampsia. Prog Mol Biol Transl Sci (2017) 0.75
Human placental growth hormone in normal and abnormal fetal growth. Biomed Rep (2017) 0.75
Decreased Homodimerization and Increased TIMP-1 Complexation of Uteroplacental and Uterine Arterial Matrix Metalloproteinase-9 during Hypertension-in-Pregnancy. Biochem Pharmacol (2017) 0.75
Increased Vascular and Uteroplacental Matrix Metalloproteinase-1 and -7 Levels and Collagen I Deposition in Hypertension-in-Pregnancy. Role of TNF. Am J Physiol Heart Circ Physiol (2017) 0.75
The prediction of late-onset preeclampsia: Results from a longitudinal proteomics study. PLoS One (2017) 0.75
Novel marker for the detection of sickle cell nephropathy: soluble FMS-like tyrosine kinase-1 (sFLT-1). Pediatr Nephrol (2015) 0.75
Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med (2004) 14.00
Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest (2003) 13.72
Establishing functional speech in echolalic children. Behav Res Ther (1967) 11.82
Vitamin D-binding protein and vitamin D status of black Americans and white Americans. N Engl J Med (2013) 9.87
Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med (2006) 7.06
Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis. Nat Med (2011) 6.35
Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int (2007) 6.35
Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med (2006) 6.21
Preeclampsia: an endothelial cell disorder. Am J Obstet Gynecol (1989) 5.73
A pilot basic education program for school dropouts incorporating a token reinforcement system. Behav Res Ther (1968) 4.94
DNA copy number amplifications in human neoplasms: review of comparative genomic hybridization studies. Am J Pathol (1998) 4.61
Inbreeding avoidance in animals. Trends Ecol Evol (1996) 3.79
Excess circulating angiopoietin-2 may contribute to pulmonary vascular leak in sepsis in humans. PLoS Med (2006) 3.72
Approaches to sudden death from coronary heart disease. Circulation (1971) 3.58
A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate. J Matern Fetal Neonatal Med (2008) 3.39
Pilot study of extracorporeal removal of soluble fms-like tyrosine kinase 1 in preeclampsia. Circulation (2011) 3.33
Application of operant conditioning procedures to the behavior problems of an autistic child: a follow-up and extension. Behav Res Ther (1967) 3.23
The two stage model of preeclampsia: variations on the theme. Placenta (2008) 2.78
Sequential changes in antiangiogenic factors in early pregnancy and risk of developing preeclampsia. Hypertension (2007) 2.77
Urinary placental growth factor and risk of preeclampsia. JAMA (2005) 2.76
Vascular endothelial growth factor is an important determinant of sepsis morbidity and mortality. J Exp Med (2006) 2.75
Bioavailable vitamin D is more tightly linked to mineral metabolism than total vitamin D in incident hemodialysis patients. Kidney Int (2012) 2.74
DNA copy number losses in human neoplasms. Am J Pathol (1999) 2.73
Vascular endothelial growth factor-A and aldosterone: relevance to normal pregnancy and preeclampsia. Hypertension (2013) 2.70
Pathogenesis of preeclampsia. Annu Rev Pathol (2010) 2.66
Recombinant vascular endothelial growth factor 121 attenuates hypertension and improves kidney damage in a rat model of preeclampsia. Hypertension (2007) 2.62
Evidence for high-energy extraterrestrial neutrinos at the IceCube detector. Science (2013) 2.56
Vitamin D-binding protein modifies the vitamin D-bone mineral density relationship. J Bone Miner Res (2011) 2.55
Preeclampsia, a disease of the maternal endothelium: the role of antiangiogenic factors and implications for later cardiovascular disease. Circulation (2011) 2.55
Bat flight generates complex aerodynamic tracks. Science (2007) 2.50
Angiopoietin-2 may contribute to multiple organ dysfunction and death in sepsis*. Crit Care Med (2012) 2.32
Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia. Thromb Haemost (1992) 2.31
Vitamin D deficiency and cardiovascular events in patients with coronary heart disease: data from the Heart and Soul Study. Am J Epidemiol (2014) 2.30
Cardiac angiogenic imbalance leads to peripartum cardiomyopathy. Nature (2012) 2.27
Activated vitamin D attenuates left ventricular abnormalities induced by dietary sodium in Dahl salt-sensitive animals. Proc Natl Acad Sci U S A (2007) 2.25
Leading-edge vortex improves lift in slow-flying bats. Science (2008) 2.24
Clinical characterization and outcomes of preeclampsia with normal angiogenic profile. Hypertens Pregnancy (2013) 2.22
Circulating angiogenic factors in the pathogenesis and prediction of preeclampsia. Hypertension (2005) 2.22
Elevated levels of S-nitrosoalbumin in preeclampsia plasma. Circ Res (2001) 2.21
Cocaine and tobacco use and the risk of spontaneous abortion. N Engl J Med (1999) 2.20
Early outcomes among those initiating chronic dialysis in the United States. Clin J Am Soc Nephrol (2011) 2.17
The C3(1)/SV40 T-antigen transgenic mouse model of mammary cancer: ductal epithelial cell targeting with multistage progression to carcinoma. Oncogene (2000) 2.15
Behavioral risk factors for disease and preventive health practices among lesbians. Am J Public Health (2001) 2.12
First trimester placental growth factor and soluble fms-like tyrosine kinase 1 and risk for preeclampsia. J Clin Endocrinol Metab (2004) 2.11
Preeclampsia: the role of angiogenic factors in its pathogenesis. Physiology (Bethesda) (2009) 2.10
Angiopoietin 2 is a partial agonist/antagonist of Tie2 signaling in the endothelium. Mol Cell Biol (2009) 2.09
Preeclampsia and angiogenic imbalance. Annu Rev Med (2008) 2.05
Artifactual pulse-oximetry estimation in neonates. Lancet (1994) 2.04
Circulating levels of the antiangiogenic marker sFLT-1 are increased in first versus second pregnancies. Am J Obstet Gynecol (2005) 2.03
Endothelial dysfunction: a link among preeclampsia, recurrent pregnancy loss, and future cardiovascular events? Hypertension (2006) 2.02
Terahertz spin current pulses controlled by magnetic heterostructures. Nat Nanotechnol (2013) 2.01
First observation of PeV-energy neutrinos with IceCube. Phys Rev Lett (2013) 2.00
Molecular mechanisms of preeclampsia. Microvasc Res (2007) 1.90
PGC-1α promotes recovery after acute kidney injury during systemic inflammation in mice. J Clin Invest (2011) 1.88
Angiogenic factors and the risk of adverse outcomes in women with suspected preeclampsia. Circulation (2012) 1.88
Transcriptionally active syncytial aggregates in the maternal circulation may contribute to circulating soluble fms-like tyrosine kinase 1 in preeclampsia. Hypertension (2012) 1.86
Comparative analysis of brain structure, metabolism, and cognition in myotonic dystrophy 1 and 2. Neurology (2010) 1.84
A model for intracellular translocation of protein kinase C involving synergism between Ca2+ and phorbol esters. Nature (1985) 1.83
Recombinant vascular endothelial growth factor 121 infusion lowers blood pressure and improves renal function in rats with placentalischemia-induced hypertension. Hypertension (2009) 1.82
Investigation of human brain hemodynamics by simultaneous near-infrared spectroscopy and functional magnetic resonance imaging. Med Phys (2001) 1.81
Diagnostic utility of soluble fms-like tyrosine kinase 1 and soluble endoglin in hypertensive diseases of pregnancy. Am J Obstet Gynecol (2007) 1.80
Is oxidative stress the link in the two-stage model of pre-eclampsia? Lancet (1999) 1.80
Soluble Fms-like tyrosine kinase 1 and endothelial dysfunction in the pathogenesis of preeclampsia. Pediatr Res (2005) 1.78
Filgrastim in patients with chemotherapy-induced febrile neutropenia. A double-blind, placebo-controlled trial. Ann Intern Med (1994) 1.73
Severe lymphocytopenia and interstitial pneumonia in patients treated with paclitaxel and simultaneous radiotherapy for non-small-cell lung cancer. J Clin Oncol (1996) 1.73
Uric acid, endothelial dysfunction and pre-eclampsia: searching for a pathogenetic link. J Hypertens (2004) 1.71
Pathophysiology of the clinical manifestations of preeclampsia. Clin J Am Soc Nephrol (2007) 1.69
Pre-eclampsia: clinical manifestations and molecular mechanisms. Nephron Clin Pract (2007) 1.67
Cytomegalovirus-induced mirror syndrome associated with elevated levels of circulating antiangiogenic factors. Obstet Gynecol (2007) 1.67
A retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens including platinum and docetaxel for recurrent non-small-cell lung cancer. Lung Cancer (2003) 1.63
Can APC mutation analysis contribute to therapeutic decisions in familial adenomatous polyposis? Experience from 680 FAP families. Gut (2001) 1.63
Interferon-α and angiogenic dysregulation in pregnant lupus patients who develop preeclampsia. Arthritis Rheumatol (2015) 1.61
Role of intracellular calcium mobilization in the regulation of protein kinase C-mediated membrane processes. Nature (1985) 1.61
Interaction of protein kinase C with membranes is regulated by Ca2+, phorbol esters, and ATP. J Biol Chem (1985) 1.61
Circulating procoagulant microparticles in women with unexplained pregnancy loss: a new insight. Thromb Haemost (2001) 1.60
Pre-eclampsia, soluble fms-like tyrosine kinase 1, and the risk of reduced thyroid function: nested case-control and population based study. BMJ (2009) 1.59
Antibodies to macromolecular platelet factor 4-heparin complexes in heparin-induced thrombocytopenia: a study of 44 cases. Thromb Haemost (1995) 1.58
Angiogenic factors and preeclampsia. Semin Nephrol (2011) 1.58
Protein kinase C phosphorylates topoisomerase II: topoisomerase activation and its possible role in phorbol ester-induced differentiation of HL-60 cells. Proc Natl Acad Sci U S A (1986) 1.56
Clinical outcomes in kidney transplant recipients receiving long-term therapy with inhibitors of the mammalian target of rapamycin. Am J Transplant (2011) 1.56
Reduction of blood loss and transfusion requirement by aprotinin in posterior lumbar spine fusion. Anesth Analg (1999) 1.56
Study of the mass and spin-parity of the Higgs boson candidate via its decays to Z boson pairs. Phys Rev Lett (2013) 1.56
Transient electronic structure and melting of a charge density wave in TbTe3. Science (2008) 1.56
Granulocyte colony-stimulating factor and neutrophil recovery after high-dose chemotherapy and autologous bone marrow transplantation. Lancet (1989) 1.54
VEGF and TGF-beta are required for the maintenance of the choroid plexus and ependyma. J Exp Med (2008) 1.54
Near-infrared study of fluctuations in cerebral hemodynamics during rest and motor stimulation: temporal analysis and spatial mapping. Med Phys (2000) 1.54
Endostatin causes G1 arrest of endothelial cells through inhibition of cyclin D1. J Biol Chem (2002) 1.51
The glomerular injury of preeclampsia. J Am Soc Nephrol (2007) 1.50
Protease activity of urokinase and tumor progression in a syngeneic mammary cancer model. J Natl Cancer Inst (2006) 1.49
Invasive cytotrophoblasts manifest evidence of oxidative stress in preeclampsia. Am J Pathol (2000) 1.48
Familial factors in the association between preeclampsia and later ESRD. Clin J Am Soc Nephrol (2012) 1.47
Species-specific variation in SIV disease progression between Chinese and Indian subspecies of rhesus macaque. J Med Primatol (2002) 1.46
Post-transplant hypophosphatemia: Tertiary 'Hyper-Phosphatoninism'? Kidney Int (2006) 1.45
Prevalence and severity of disordered mineral metabolism in Blacks with chronic kidney disease. Kidney Int (2008) 1.44
Further observations of true mosaic trisomy 17 ascertained in amniotic fluid cell cultures. Prenat Diagn (1998) 1.44
[Is there a correlation between C-reactive protein and calcification inhibitors with cardiovascular parameters and risk factors in hemodialysis patients?]. Dtsch Med Wochenschr (2007) 1.43
Prognostic impact of an activation of coagulation in lung cancer. Ann Oncol (1997) 1.42
Hypothesis: Uric acid, nephron number, and the pathogenesis of essential hypertension. Kidney Int (2004) 1.42
The expression profile of C19MC microRNAs in primary human trophoblast cells and exosomes. Mol Hum Reprod (2012) 1.41
Are esterases involved in multidrug resistance? J Natl Cancer Inst (1993) 1.41